VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

Shares of Viridian Therapeutics, Inc. (VRDN) surged 32.1% on Sept. 10 after the company announced positive top-line data from the phase III THRIVE study, which evaluated its lead pipeline drug, veligrotug (formerly known as VRDN-001) for treating patients with active thyroid eye disease (TED). The THRIVE study met all the primary and all secondary endpoints by demonstrating highly statistically significant improvements in all measured signs and symptoms of TED at week 15 of treatment with veligrotug, an ant ...